Compare Firy Inc. (FIRY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Firy Inc. trades at $11.97 (market cap $196.97M), while Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 11.7× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FIRY | RXRX | |
|---|---|---|
Market Cap | $196.97M | $2.31B |
Volume | 155,239 | 40,478,768 |
Sector | Technology | Health |
52-Week High | $13.10 | $6.79 |
52-Week Low | $2.28 | $2.84 |
Typical Hold Time | 13 Days | 22 Days |
Enterprise Value | $165.57M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $12.02, down 3.69% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company shows a high gross margin of 87.76% but negative net income margin of -60.23% and significant cash burn. Recent developments include a $719 million legal victory and board additions, though revenue has declined from $270M in 2022 to $104M in 2025.
The outlook remains challenging with persistent losses and cash burn offset by potential from legal wins. Investment opportunity exists if the company can monetize legal judgments and stabilize operations, but risks include continued operational losses and uncertainty around cash flow sustainability.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
